- Home
- ENGS vs ONCY Comparison
ENGS vs ONCY Comparison
Compare ENGS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGS
- ONCY
- Stock Information
- Founded
- ENGS 1998
- ONCY 1998
- Country
- ENGS United Kingdom
- ONCY Canada
- Employees
- ENGS N/A
- ONCY N/A
- Industry
- ENGS
- ONCY Pharmaceuticals and Biotechnology
- Sector
- ENGS
- ONCY Health Care
- Exchange
- ENGS NYSE
- ONCY Nasdaq
- Market Cap
- ENGS 45.6M
- ONCY 49.1M
- IPO Year
- ENGS 2025
- ONCY 1999
- Fundamental
- Price
- ENGS $1.67
- ONCY $0.69
- Analyst Decision
- ENGS
- ONCY Strong Buy
- Analyst Count
- ENGS 0
- ONCY 4
- Target Price
- ENGS N/A
- ONCY $4.33
- AVG Volume (30 Days)
- ENGS 620.5K
- ONCY 1.4M
- Earning Date
- ENGS 01-01-0001
- ONCY 07-31-2025
- Dividend Yield
- ENGS N/A
- ONCY N/A
- EPS Growth
- ENGS N/A
- ONCY N/A
- EPS
- ENGS N/A
- ONCY N/A
- Revenue
- ENGS $12,134,254.00
- ONCY N/A
- Revenue This Year
- ENGS N/A
- ONCY N/A
- Revenue Next Year
- ENGS N/A
- ONCY N/A
- P/E Ratio
- ENGS N/A
- ONCY N/A
- Revenue Growth
- ENGS 59.88
- ONCY N/A
- 52 Week Low
- ENGS $1.36
- ONCY $0.33
- 52 Week High
- ENGS $10.24
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- ENGS N/A
- ONCY 69.96
- Support Level
- ENGS N/A
- ONCY $0.56
- Resistance Level
- ENGS N/A
- ONCY $0.37
- Average True Range (ATR)
- ENGS 0.00
- ONCY 0.07
- MACD
- ENGS 0.00
- ONCY 0.04
- Stochastic Oscillator
- ENGS 0.00
- ONCY 83.26
About ENGS ENERGYS GROUP LTD
Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.